ライフサイエンスコーパス: dDAVP

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します

1 dDAVP decreased phosphorylation of both JNK1/2 (T183/Y18

2 dDAVP induced gene expression of P2X(1), which localized

3 dDAVP, on the other hand, had no effect.

4 ydration, treated with desmopressin acetate (dDAVP), or water loaded.

5 -3-3 interaction that was modulated by acute dDAVP treatment.

6 vels was observed in the outer medulla after dDAVP infusion.

7 with the type 2 vasopressin receptor agonist dDAVP increased mRNA and protein levels of AQP2 alongsid

8 ther forskolin or the V(2)-selective agonist dDAVP would increase apical membrane expression of UT-A1

9 rivation or administration of the VR agonist dDAVP did not increase urine osmolality of AC6-deficient

10 First, the vasopressin receptor-2 agonist, dDAVP, was delivered to the renal medulla resulting in a

11 Rats received the vasopressin analog dDAVP by osmotic minipump plus either a daily water load

12 The V2 receptor-specific vasopressin analog dDAVP increased Ser(P)269-AQP2 abundance more than 10-fo

13 fusion of the antidiuretic hormone analogue, dDAVP, resulted in systemic hypotonicity in trpv4-/- mic

14 Dehydration and dDAVP stimulated translocation of AQP-2 from intracellul

15 priately stimulated by water deprivation and dDAVP.

16 Forskolin and dDAVP significantly increased UT-A1 abundance in the api

17 54 phosphopeptides decreased in abundance by dDAVP showed a predominance of so-called "proline-direct

18 ysis of the 273 phosphopeptides increased by dDAVP showed a predominance of so-called "basophilic" mo

19 nd AQP3 mRNA, and cAMP production induced by dDAVP (desmopressin).

20 divided into two groups: control (continued dDAVP) and water-loaded (continued dDAVP plus a daily or

21 continued dDAVP) and water-loaded (continued dDAVP plus a daily oral water load).

22 nce of the vasopressin analog, desmopressin (dDAVP).

23 nt responded to large doses of desmopressin (dDAVP) which decreased urine volume from 10 to 4 I/day.

24 rsed by water restriction reestablished high dDAVP-stimulated kidney levels of AQP-2 after 4 d of wat

25 Osmotic minipumps to infuse dDAVP, the V2-selective vasopressin agonist (5 ng/h) for

26 Furthermore, AC6-deficient mice lacked dDAVP-promoted inner medullary cAMP formation and phosph

27 re (SILAC) with two treatment groups (0.1 nM dDAVP or vehicle for 30 min), we carried out quantificat

28 In the absence of dDAVP, P2Y(1) and P2Y(4) receptors localized to the apic

29 When clinically tested, infusion of dDAVP at variable doses produced a partial increase in t

30 ical membrane labeling of ROMK in the TAL of dDAVP-treated rats, as assessed by immunocytochemical an

31 t in polyuria and polydipsia with the use of dDAVP (1-desamino-8-D-arginine-vasopressin).

32 wnregulation of AQP-2 expression compared to dDAVP-infused control rats was seen in the inner medulla

33 Results were compared to dDAVP-infused rats fed solid chow.

34 Basolateral exposure to dDAVP induced AQP2 localization to the apical membrane,

35 a decrease in phosphorylation in response to dDAVP in vivo.

36 hese proline-directed kinases in response to dDAVP.

37 s did not change in abundance in response to dDAVP.

38 ist, or 1-desamino-8-D-arginine vasopressin (dDAVP, 5 ng), a V2 agonist.

39 ion of 1-deamino-(8-D-arginine)-vasopressin (dDAVP), a vasopressin V2 receptor-selective agonist, for

40 t with 1-deamino-[8-D-arginine]-vasopressin (dDAVP) by osmotic mini-pump, rats were divided into two

41 ups of 1-deamino-[8-D-arginine]-vasopressin (dDAVP)-infused rats were water-loaded; after establishme

42 Water loading (with dDAVP infusion) resulted in increased whole-kidney abund

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。